Sygnature Discovery, providers of drug discovery solutions, has appointed Dr Charles Woler as Chairman.
Dr Woler has held multiple key roles in the sector, including CEO at Roche France, Executive Chairman for Europe at SmithKline Beecham, and CEO at Cadus Pharmaceutical in the US.
Woler said: “Sygnature has a reputation for delivering quality scientific work with a culture that enables very effective communication and collaboration, plus a track record of developing compounds into the clinic. I believe it is a company that is going places, and I look forward to playing a part in fulfilling its vast potential at such an exciting time in the world of drug discovery.”
Dr Simon Hirst, CEO and founder of Sygnature Discovery, said that Dr Woler, “will help shape the strategic approach of our thriving drug discovery business” as the company looks to accelerate growth.